⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CVKD News
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
globenewswire.com
CVKD
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
globenewswire.com
CVKD
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
globenewswire.com
CVKD